Menu Search
Equities

Episurf Medical AB

EPIS B:STO

Episurf Medical AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.1706
  • Today's Change-0.004 / -2.40%
  • Shares traded462.12k
  • 1 Year change-78.53%
  • Beta1.1626
Data delayed at least 15 minutes, as of Sep 20 2024 16:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in SEK

The one analyst offering a 12 month price target expects Episurf Medical AB share price to rise to 1.30 in the next year from the last price of 0.1748.
High643.7%1.30
Med643.7%1.30
Low643.7%1.30

Earnings history & estimates in SEK

On Feb 23, 2016, losses of -0.678 per share.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate-13.87%
Episurf Medical AB reported annual 2023 losses of -0.278 per share on Feb 09, 2024.
Average growth rate+16.31%
More ▼

Revenue history & estimates in SEK

of 3.10m. This bettered the 3.00m estimate of the one analyst covering the company.
Average growth rate+12.60%
Episurf Medical AB (publ) had revenues for the full year 2023 of 10.60m. This was 60.61% above the prior year's results.
Average growth rate+23.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.